Sign In
Buy NDAQ
$81.61
-0.88 (-1.07%)
At Close: Jun 24, 2026
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 07'th Mar 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
04:05pm, Friday, 07'th Mar 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securit
Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements
04:05pm, Friday, 07'th Mar 2025
Ra'anana, Israel, March 07, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (the “Company”) (Nasdaq: RVSN), a technology company at the forefront of revolutionizing railway safety and the data-related m
Nasdaq Lags Industry, Trades at a Discount: Time to Buy the Dip?
04:00pm, Friday, 07'th Mar 2025
NDAQ is set to grow on the back of its increasing on-trading revenue base, impressive organic growth and investments in proprietary data, supported by a solid capital position.
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
02:10pm, Friday, 07'th Mar 2025
Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase
Nasdaq targeting 2026 launch of 24-hour trading
12:53pm, Friday, 07'th Mar 2025
Nasdaq Inc (NASDAQ:NDAQ) is looking into implementing 24-hour trading Monday through Friday, president Tal Cohen revealed on Friday. In a post on LinkedIn, Cohen said Nasdaq has begun engaging with re
Nasdaq Enters Correction: 5 Bargain Stocks in the ETF
11:30am, Friday, 07'th Mar 2025
We highlight five bargain stocks in the Nasdaq ETF that are worth considering.
Lottery.com Inc. Regains Full Compliance with Nasdaq's Continued Listing Rules
11:00am, Friday, 07'th Mar 2025
FORT WORTH, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lottery.com Inc. (NASDAQ: LTRY; LTRYW) (“Lottery.com” or “the Company”) received a notice (the “Notice”) from The Nasdaq St
Live Nasdaq Composite: Stocks Lack Conviction, NVDA, AAPL and AVGO Rise
10:33am, Friday, 07'th Mar 2025
The markets have a lot to process after what's been a tumultuous week, and stocks are moving with a lack of conviction.
2 Top AI Stocks to Buy in the Nasdaq Correction
09:58am, Friday, 07'th Mar 2025
Artificial intelligence (AI) stocks have roared higher over the past couple of years as investors piled in, aiming to invest early in the next big game-changing technology. Through AI, companies may b
S&P 500 and Nasdaq 100: Could a Weak Jobs Report Spark Another Selloff in US Indices Today?
09:33am, Friday, 07'th Mar 2025
S&P 500 and Nasdaq 100 slide as weak jobs data fuels rate cut speculation. Can US indices recover, or is more downside ahead?
4 Reasons to Buy the Dip in Nasdaq ETFs
09:30am, Friday, 07'th Mar 2025
Wall Street has been in a wavering mode this week due to the tariff fatigue. The Nasdaq has dropped more than 4% week to date, while the Dow and S&P 500 have slid around 2.9% and 3.6%, respectively.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Mar 2025
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Mar 2025
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (A
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 07'th Mar 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicin
